2009

2 December 2009
The Scientist Magazine Recognizes febits HybSelect Among the Winners of Top 10 Innovations of 2009

19 November 2009
Novaled Wins Audemars Piguet European Cleantech Entrepreneur of the Year Award

10 November 2009
Ascendis Pharma initiates Phase I clinical study of ACP-001,
a once-weekly human growth hormone product

5 November 2009
Frost & Sullivan Honours Fludicon with European Automotive Advanced Suspension Technologies Excellence in Research Award

29 October 2009
Komfort und Sicherheit auch bei extremen Fahrsituationen: Aktive Stoßdämpfung wird den Automobil-Bereich verändern

13  October 2009
MicroRNA Biomarkers provide reliable diagnosis from blood samples

07 October 2009
IDEA updates on Diractin® (ketoprofen in Transfersome® gel) status

28 September 2009
Life Technologies and febit Team to offer new solution for targeted Re-sequencing in Large-scale Genomic Studies

15 June 2009
Cenix BioScience expands relationship with AstraZeneca, signing multi-project research agreement

14 May 2009
White record OLEDs of Dresden University and Novaled surpass efficiency of fluorescent tubes

14 April 2009
Febit, Nearing Settlement with Codon Devices, Reconsiders Its Place in Synthetic Bio Market

07 April 2009
IDEA reports results from a prospective 3 years phase lll study of Diractin® (ketoprofen in Transfersome® gel)

24 March 2009
Novaled AG announces that it will work together with Holst Centre on Organic Thin Film Transistors (OTFT) using the Novaled PIN OLED® technology and materials.<B/>

02 February 2009
Cenix BioScience signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery.

05 February 2009
US Patent Office grants a new patent to IDEA AG, which also covers the targeted analgesic product Diractin® (ketoprofen in Transfersome® gel)

14 January 2009
Novaled AG secured € 8,5 Million equity financing
The company closed an internal round of financing to sustain its leading position in energy saving OLED's.